IN2014DN10576A - - Google Patents

Info

Publication number
IN2014DN10576A
IN2014DN10576A IN10576DEN2014A IN2014DN10576A IN 2014DN10576 A IN2014DN10576 A IN 2014DN10576A IN 10576DEN2014 A IN10576DEN2014 A IN 10576DEN2014A IN 2014DN10576 A IN2014DN10576 A IN 2014DN10576A
Authority
IN
India
Prior art keywords
bruton
inhibitors
compositions
useful
same
Prior art date
Application number
Other languages
English (en)
Inventor
Brian T Hopkins
Patrick Conlon
Timothy R Chan
Tracy J Jenkins
Xiongwei Cai
Michael Humora
Xianglin Shi
Ross A Miller
Andrew Thompson
Original Assignee
Biogen Idec Inc
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Sunesis Pharmaceuticals Inc filed Critical Biogen Idec Inc
Publication of IN2014DN10576A publication Critical patent/IN2014DN10576A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IN10576DEN2014 2012-06-08 2013-06-07 IN2014DN10576A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657360P 2012-06-08 2012-06-08
PCT/US2013/044800 WO2013185084A1 (en) 2012-06-08 2013-06-07 Pyrimidinyl tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN10576A true IN2014DN10576A (ja) 2015-08-28

Family

ID=49712704

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10576DEN2014 IN2014DN10576A (ja) 2012-06-08 2013-06-07

Country Status (30)

Country Link
US (5) US9394277B2 (ja)
EP (3) EP3385263B1 (ja)
JP (6) JP6214643B2 (ja)
KR (4) KR102102587B1 (ja)
CN (3) CN104540385B (ja)
AR (1) AR091273A1 (ja)
AU (5) AU2013271407B2 (ja)
BR (2) BR112014030655B1 (ja)
CA (2) CA2875799C (ja)
CY (1) CY1120638T1 (ja)
DK (1) DK2858499T3 (ja)
EA (2) EA201790418A1 (ja)
ES (2) ES2684268T3 (ja)
HK (1) HK1209284A1 (ja)
HR (1) HRP20181294T1 (ja)
HU (1) HUE039897T2 (ja)
IL (2) IL235938B (ja)
IN (1) IN2014DN10576A (ja)
LT (1) LT2858499T (ja)
MX (2) MX363672B (ja)
NZ (1) NZ702715A (ja)
PH (2) PH12014502699A1 (ja)
PL (1) PL2858499T3 (ja)
PT (1) PT2858499T (ja)
RS (1) RS57978B1 (ja)
SG (2) SG10201708535UA (ja)
SI (1) SI2858499T1 (ja)
TW (3) TWI592406B (ja)
WO (1) WO2013185084A1 (ja)
ZA (1) ZA201409255B (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3461824B1 (en) * 2009-09-04 2021-08-25 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
TWI675833B (zh) * 2013-12-11 2019-11-01 美商百健Ｍａ公司 布魯頓氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶之聯芳基抑制劑
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
US9688629B2 (en) 2014-10-24 2017-06-27 Bristol-Myers Squibb Company Indole carboxamide compounds
SG11201900515PA (en) * 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors
JP7331843B2 (ja) 2018-04-27 2023-08-23 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
CN117281803A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
WO2023081709A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
EP4448523A1 (en) 2021-12-14 2024-10-23 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1624A (en) * 1840-06-10 Cooking-stove
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
BR0109467A (pt) 2000-03-17 2003-06-03 Bristol Myers Squibb Pharma Co Composto derivados de (beta)-aminoácidos cìclicos, composição farmacêutica, método de tratamento de condições ou doenças mediadas por mps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso de composto
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
SI1294724T1 (sl) 2000-06-26 2006-08-31 Pfizer Prod Inc Pirolo(2,3-d)primidinske spojine kot imunosupresivna sredstva
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US20050143372A1 (en) 2001-10-30 2005-06-30 Shomir Ghosh Compounds, pharmaceutical compositions and methods of use therefor
EP1442039A1 (en) 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
DK1678166T3 (da) 2003-10-14 2009-11-09 Univ Arizona State Proteinkinaseinhibitorer
WO2006073419A2 (en) * 2004-04-01 2006-07-13 Gang Zheng Lipoprotein nanoplatforms
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
TW200621760A (en) 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
ZA200704476B (en) * 2004-11-04 2008-09-25 Vertex Pharma Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
KR101351209B1 (ko) 2004-12-03 2014-02-06 머크 샤프 앤드 돔 코포레이션 Ｃｂ1 길항제로서 치환된 피페라진
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
BRPI0620386A2 (pt) * 2005-12-21 2011-12-20 Schering Corp composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição
WO2008005368A2 (en) 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
EP2059305A2 (en) 2006-07-26 2009-05-20 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
PL2529621T3 (pl) 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
CN101674831A (zh) * 2007-03-02 2010-03-17 先灵公司 用于治疗糖尿病或疼痛的哌啶基哌啶和哌嗪基哌啶
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
BRPI0811898A2 (pt) 2007-06-01 2019-09-24 Glaxosmithkline Llc composto, composição farmacêutica, métodos para tratar um neoplasma suscetível e um câncer em um mamífero, processo para preparar um composto, e, uso de um composto.
CA2710462C (en) * 2008-02-05 2015-11-24 F. Hoffmann-La Roche Ag Pyridinones and pyridazinones
JP2011519049A (ja) 2008-04-29 2011-06-30 イミューンエクサイト インコーポレイテッド 免疫調節組成物およびその使用方法
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
CN102325753B (zh) * 2008-12-19 2014-09-10 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
EP3828185A3 (en) * 2009-01-06 2021-09-01 Dana Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
CN102448966A (zh) 2009-05-25 2012-05-09 桑多斯股份公司 生产头孢托罗酯的方法
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
EP3461824B1 (en) 2009-09-04 2021-08-25 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
US8685880B2 (en) 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
EP3080122B1 (en) 2013-12-11 2018-10-31 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
TWI675833B (zh) 2013-12-11 2019-11-01 美商百健Ｍａ公司 布魯頓氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶之聯芳基抑制劑
US20170298446A1 (en) 2014-10-03 2017-10-19 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance

Also Published As

Publication number Publication date
KR102468430B1 (ko) 2022-11-21
PL2858499T3 (pl) 2019-03-29
BR112014030655B1 (pt) 2021-04-20
JP2021073298A (ja) 2021-05-13
BR112014030655A8 (pt) 2018-01-02
BR112014030655A2 (pt) 2017-06-27
AU2013271407A1 (en) 2015-01-22
CA2875799C (en) 2021-03-23
CN109305959B (zh) 2022-02-08
KR20150036020A (ko) 2015-04-07
AU2017201536B2 (en) 2019-03-07
IL235938A0 (en) 2015-02-01
TWI719209B (zh) 2021-02-21
ZA201409255B (en) 2015-12-23
KR20220154850A (ko) 2022-11-22
US20150158843A1 (en) 2015-06-11
JP2017193583A (ja) 2017-10-26
US9394277B2 (en) 2016-07-19
EP2858499B1 (en) 2018-05-16
KR20210072139A (ko) 2021-06-16
US10618887B2 (en) 2020-04-14
US20190047986A1 (en) 2019-02-14
TW201805279A (zh) 2018-02-16
HUE039897T2 (hu) 2019-02-28
CN104540385B (zh) 2018-06-05
EP3385263A1 (en) 2018-10-10
EA027823B1 (ru) 2017-09-29
EP3385263B1 (en) 2020-07-22
AU2019203476B2 (en) 2021-01-28
JP2015518903A (ja) 2015-07-06
AU2017201536A1 (en) 2017-03-23
JP2023052415A (ja) 2023-04-11
TW202142535A (zh) 2021-11-16
US9944622B2 (en) 2018-04-17
PH12014502699B1 (en) 2015-02-02
CA2875799A1 (en) 2013-12-12
RS57978B1 (sr) 2019-01-31
MX2014015044A (es) 2015-09-22
JP2021073299A (ja) 2021-05-13
EA201492056A1 (ru) 2015-05-29
HRP20181294T1 (hr) 2018-10-05
WO2013185084A1 (en) 2013-12-12
PT2858499T (pt) 2018-10-24
PH12018501463A1 (en) 2019-03-04
CN109305959A (zh) 2019-02-05
EP2858499A4 (en) 2016-01-20
MX2019003618A (es) 2019-07-18
HK1209284A1 (en) 2016-04-01
NZ702715A (en) 2016-11-25
ES2834333T3 (es) 2021-06-17
AU2022275504A1 (en) 2023-01-05
TW201410668A (zh) 2014-03-16
ES2684268T3 (es) 2018-10-02
EP3753934A1 (en) 2020-12-23
CN104540385A (zh) 2015-04-22
IL277951A (en) 2020-11-30
EA201790418A1 (ru) 2017-11-30
DK2858499T3 (en) 2018-08-20
AU2019203476A1 (en) 2019-06-06
EP2858499A1 (en) 2015-04-15
SG11201408173WA (en) 2015-01-29
US20160304494A1 (en) 2016-10-20
CN113549055A (zh) 2021-10-26
MX363672B (es) 2019-03-29
CA3108186A1 (en) 2013-12-12
AR091273A1 (es) 2015-01-21
US20210017155A1 (en) 2021-01-21
JP6214643B2 (ja) 2017-10-18
SG10201708535UA (en) 2017-11-29
CY1120638T1 (el) 2019-12-11
TWI592406B (zh) 2017-07-21
IL235938B (en) 2020-10-29
JP2019077728A (ja) 2019-05-23
US20230174511A1 (en) 2023-06-08
TWI792158B (zh) 2023-02-11
LT2858499T (lt) 2018-09-10
BR122021002178B1 (pt) 2022-03-22
AU2021202412A1 (en) 2021-05-20
KR102102587B1 (ko) 2020-04-22
PH12014502699A1 (en) 2015-02-02
SI2858499T1 (sl) 2018-10-30
KR20200043497A (ko) 2020-04-27
AU2013271407B2 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
PH12018501463A1 (en) Pyrimidinyl tyrosine kinase inhibitors
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
IN2015DN00127A (ja)
MX2014010849A (es) Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2015015421A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
MY160734A (en) Besylate salt of a btk inhibitor
MX2015015417A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
WO2013185082A3 (en) Inhibitors of bruton's tyrosine kinase
IL259863B (en) Polycyclic compounds as inhibitors of proton tyrosine kinase
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MA39824A (fr) Composés azole amido-substitués
MX2019000884A (es) Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton.
NZ743260A (en) Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors
NZ737572A (en) Intermediate compounds for the preparation of bipiperidine-2-one compounds